MX2010009961A - Composicion transmucosica mejorada y forma de dosificacion. - Google Patents
Composicion transmucosica mejorada y forma de dosificacion.Info
- Publication number
- MX2010009961A MX2010009961A MX2010009961A MX2010009961A MX2010009961A MX 2010009961 A MX2010009961 A MX 2010009961A MX 2010009961 A MX2010009961 A MX 2010009961A MX 2010009961 A MX2010009961 A MX 2010009961A MX 2010009961 A MX2010009961 A MX 2010009961A
- Authority
- MX
- Mexico
- Prior art keywords
- dosage form
- active compound
- transmucosal
- composition
- osmolality
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000004615 ingredient Substances 0.000 abstract 2
- 206010020852 Hypertonia Diseases 0.000 abstract 1
- 239000003833 bile salt Substances 0.000 abstract 1
- ZISSAWUMDACLOM-UHFFFAOYSA-N methyl-t-butylethan Natural products CC(C)C(C)(C)C ZISSAWUMDACLOM-UHFFFAOYSA-N 0.000 abstract 1
- 210000004400 mucous membrane Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 229960003708 sumatriptan Drugs 0.000 abstract 1
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 abstract 1
- -1 triptan compound Chemical class 0.000 abstract 1
- 229960001360 zolmitriptan Drugs 0.000 abstract 1
- UTAZCRNOSWWEFR-ZDUSSCGKSA-N zolmitriptan Chemical compound C=1[C]2C(CCN(C)C)=CN=C2C=CC=1C[C@H]1COC(=O)N1 UTAZCRNOSWWEFR-ZDUSSCGKSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Abstract
La invención proporciona una composición farmacéutica transmucósica que comprende un compuesto activo, una sal biliar y un ingrediente que ajusta la osmolalidad, donde el ingrediente que ajusta la osmolalidad genera un entorno hiperosmótico localizado y mantiene un nivel de osmolalidad durante un período de tiempo suficiente para producir el transporte transmucósico de dicho compuesto activo a través del tejido mucoso, facilitado por la hipertonicidad. La invención también proporciona una forma de dosificación transmucósica sólida que contiene la composición así como un método de tratamiento que comprende su administración. En una realización, el compuesto activo es un compuesto triptán, por ejemplo, sumatriptán y zolmitriptán.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6941408P | 2008-03-14 | 2008-03-14 | |
| PCT/US2009/001626 WO2009114192A2 (en) | 2008-03-14 | 2009-03-13 | Enhanced transmucosal composition and dosage form |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2010009961A true MX2010009961A (es) | 2010-09-30 |
Family
ID=41065734
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2010009961A MX2010009961A (es) | 2008-03-14 | 2009-03-13 | Composicion transmucosica mejorada y forma de dosificacion. |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20110021583A1 (es) |
| EP (1) | EP2265250A2 (es) |
| JP (1) | JP2011514358A (es) |
| CA (1) | CA2717984C (es) |
| MX (1) | MX2010009961A (es) |
| WO (1) | WO2009114192A2 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1254670A1 (zh) | 2015-07-02 | 2019-07-26 | Civitas Therapeutics, Inc. | 曲普坦粉末用於肺部给药 |
| CA3166250A1 (en) * | 2020-02-05 | 2021-08-12 | Gregory G. Plucinski | Drug products for intranasal administration and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4968507A (en) * | 1984-06-20 | 1990-11-06 | Merck & Co., Inc. | Controlled porosity osmotic pump |
| JPH11292787A (ja) * | 1995-08-15 | 1999-10-26 | Asahi Chem Ind Co Ltd | 生理活性ペプチドを含有する経粘膜投与製剤 |
| IL127955A0 (en) * | 1996-07-11 | 1999-11-30 | Farmarc Nederland Bv | Pharmaceutical composition containing acid addition salt of basic drug |
| TWI243687B (en) * | 1998-04-21 | 2005-11-21 | Teijin Ltd | Pharmaceutical composition for application to mucosa |
| US6210699B1 (en) * | 1999-04-01 | 2001-04-03 | Watson Pharmaceuticals, Inc. | Oral transmucosal delivery of drugs or any other ingredients via the inner buccal cavity |
| AR026072A1 (es) * | 1999-10-20 | 2002-12-26 | Nycomed Gmbh | Composicion farmaceutica que contiene ciclesonida para aplicacion a la mucosa |
| CA2392810A1 (en) * | 1999-12-01 | 2001-06-07 | Natco Pharma Limited | A rapid acting freeze dired oral pharmaceutical composition for treating migraine |
| US20020147232A1 (en) * | 2000-05-26 | 2002-10-10 | Claus Sundgreen | Pharmaceutical compositions comprising desglymidodrine as an active drug substance |
| US20040248846A1 (en) * | 2003-04-22 | 2004-12-09 | Nastech Pharmaceutical Company Inc. | Intranasal administration of triptans |
| US20060002989A1 (en) * | 2004-06-10 | 2006-01-05 | Ahmed Salah U | Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same |
| US20060193908A1 (en) * | 2004-11-09 | 2006-08-31 | Burnside Beth A | Extended release formulations of poorly soluble antibiotics |
| WO2007096906A2 (en) * | 2006-02-27 | 2007-08-30 | Panacea Biotec Ltd. | Novel buccoadhesive compositions and process of preparation thereof |
-
2009
- 2009-03-13 CA CA2717984A patent/CA2717984C/en not_active Expired - Fee Related
- 2009-03-13 JP JP2010550703A patent/JP2011514358A/ja active Pending
- 2009-03-13 EP EP09719448A patent/EP2265250A2/en not_active Withdrawn
- 2009-03-13 MX MX2010009961A patent/MX2010009961A/es not_active Application Discontinuation
- 2009-03-13 WO PCT/US2009/001626 patent/WO2009114192A2/en not_active Ceased
-
2010
- 2010-08-23 US US12/860,978 patent/US20110021583A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2265250A2 (en) | 2010-12-29 |
| JP2011514358A (ja) | 2011-05-06 |
| US20110021583A1 (en) | 2011-01-27 |
| WO2009114192A3 (en) | 2010-07-08 |
| CA2717984A1 (en) | 2009-09-17 |
| WO2009114192A2 (en) | 2009-09-17 |
| CA2717984C (en) | 2013-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009003372A (es) | Formas de dosificacion de pelicula no mucoadhesiva. | |
| MX2011013201A (es) | Composiciones para tratar adiccion a drogas y para mejorar comportamiento relacionado a la adiccion. | |
| EA201190127A1 (ru) | Фармацевтические составы нитазоксанида с контролируемым высвобождением | |
| CL2010001260A1 (es) | Composicion farmaceutica que comprende una sal de estroncio y vitamina d y una ciclodextrina, donde la relacion masica entre la cantidad de vitamina d y la cantidad de ciclodextrina esta comprendida entre 1/40 y 1/800, util para tratar o prevenir osteoporosis. | |
| MY143795A (en) | Tetrahydropyridoindole derivatives | |
| MX2009004017A (es) | Usos de los compuestos carboxi-amido triazol y sus sales. | |
| DE602005021770D1 (de) | Indol-1-yl-essigsäurederivate | |
| MY164864A (en) | Indenone derivative and pharmaceutical composition comprising same | |
| PH12012500773A1 (en) | A skin external composition comprising a salt and sugar as active ingredients for preventing and treating vaginosis and the use thereof | |
| WO2006029036A3 (en) | Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis | |
| MX2009011900A (es) | Curacion de herida diabetica. | |
| WO2008070010A3 (en) | Hydroxylamine derivatives for the treatment of stroke | |
| EA200801731A1 (ru) | Составы и способы лечения тробмоцитемии | |
| TW200509992A (en) | Dosage form containing pantoprazole as active ingredient | |
| MX341660B (es) | Agonista del receptor de ghrelina para el tratamiento de caquexia. | |
| MX339096B (es) | Compuestos inhibidores de metaloproteasa a base de feniletiniltiofeno y su uso en el tratamiento del dolor y otras enfermedades. | |
| MX2010009961A (es) | Composicion transmucosica mejorada y forma de dosificacion. | |
| TW200503785A (en) | Dosage form containing (S)-pantoprazole as active ingredient | |
| ECSP12012332A (es) | Asociación de inhibidores de la xantina oxidasa y la instatina y su uso | |
| TW200611697A (en) | Generally linear effervescent oral fentanyl dosage form and methods of administering | |
| FI20135503A7 (fi) | Kysteiini tai sen johdannainen atrofisen gastriitin hoitamiseen | |
| AR066667A1 (es) | Composiciones farmaceuticas que comrenden la combinacion de un agente derivado hidrogenado de lipstatina y un agente inhibidor de hmg coa reductasa | |
| EA201201529A1 (ru) | Комбинация ингибиторов ксантиноксидазы и статинов и ее применение | |
| UA44173U (ru) | Фармацевтическая композиция в форме суппозиториев для лечения проктологических заболеваний | |
| EA200701086A1 (ru) | Производные изоксазола, их фармацевтические композиции и способ лечения невропатической боли |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |